T2 Biosystems
T2 Biosystems Q4 Revenues Jump 152 Percent on Strong Product Sales
The company said that it sold 57 T2Dx instruments in 2020, including 47 in the US, more than doubling its US installed base.
T2 Biosystems Preliminary Q4 Revenues Grow 155 Percent, Miss Estimates
The firm also announced the amendment of the terms of a loan with CRG, a global healthcare investor.
T2 Biosystems Q3 Revenues Triple, Beat Estimates
The firm also more than tripled its product sales year over year, and its CEO said he considered the quarter to be "transformational."
BARDA Exercises $10.5M Option on T2 Bio Contract
The option was exercised under a multiyear contract between T2 Bio and BARDA valued at a total of $69 million if all options are exercised.
T2 Biosystems Gets FDA EUA for SARS-CoV-2 Molecular Diagnostic Test
T2 Bio's T2SARS-CoV-2 Panel detects SARS-CoV-2 within two hours using a nasopharyngeal swab sample and runs on the firm's T2Dx instrument.
May 5, 2020
T2 Biosystems Q1 Revenues Jump 43 Percent
Apr 9, 2020
T2 Biosystems Receives Nasdaq Warning Letter
Feb 25, 2020
Oct 21, 2019